8-K: Gossamer Bio Executes 1-for-80 Reverse Stock Split

Gossamer Bio announced the effectiveness of its 1-for-80 reverse stock split and a reduction in authorized shares, aimed at regaining compliance with Nasdaq's minimum bid price requirement.

Summary

• Gossamer Bio, Inc. has completed a 1-for-80 reverse stock split of its common stock.
• This action also involved a proportionate reduction in the number of authorized shares.
• The reverse stock split became effective on September 10, 2026, at 11:59 p.m. Eastern Time.
• Shares are expected to trade on a split-adjusted basis starting September 11, 2026.
• The primary goal is to regain compliance with the Nasdaq Global Select Market's minimum bid price requirement of $1.00 per share.
• The number of authorized common shares was reduced from 4,000,000,000 to 50,000,000.
• Total authorized capital stock was reduced from 4,070,000,000 to 120,000,000.
• Fractional shares will be rounded up to the nearest whole share.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as the reverse stock split is a measure often taken by companies struggling to maintain exchange listing requirements, indicating underlying financial or market valuation challenges.

Positives

• The reverse stock split is intended to help the company regain compliance with the Nasdaq minimum bid price requirement, potentially avoiding delisting.
• Shareholders' percentage ownership and voting power remain unchanged, except for minor adjustments due to fractional share treatment.
• The company is taking proactive steps to meet listing standards.

Negatives

• A reverse stock split is often a sign of a company's stock price struggling to meet exchange requirements, suggesting underlying business or market valuation concerns.
• There is no assurance that the company will successfully regain or maintain compliance with the minimum bid price requirement.
• The reverse stock split may negatively impact the company's results of operations, business operations, reputation, and stock price volatility.

Risks

• The reverse stock split may not result in a sustained increase in the stock price or satisfy the Nasdaq minimum bid price requirement.
• The reverse stock split could negatively impact the company's operations, reputation, and stock price volatility.
• Unstable market and economic conditions, and changes in healthcare legislation, tariffs, and trade policies could adversely affect the company's business and financial condition.
• There is no guarantee that the common stock will remain listed on the Nasdaq Global Select Market.

Future Outlook

The company aims to regain compliance with the Nasdaq minimum bid price requirement through the reverse stock split, with trading expected to commence on a split-adjusted basis on September 11, 2026. However, there is no assurance of sustained compliance or continued listing on Nasdaq.

Management Comments

• The reverse stock split is intended to help the Company regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common, albeit often concerning, tactic in the biotechnology and pharmaceutical sectors when companies face challenges meeting minimum bid price requirements for major exchanges like Nasdaq. This often signals underlying concerns about market valuation or the pace of clinical development.

Corporate Governance

Stakeholder Impact

• Shareholders: Ownership percentage remains the same, but the number of shares held is reduced by a factor of 80. Fractional shares will be rounded up.
• Creditors: The reverse stock split does not directly impact the company's debt obligations.
• Employees: Equity awards and warrants are adjusted proportionally, affecting the number of shares and exercise prices.

Next Steps

• Monitor the stock's performance to ensure it meets the $1.00 minimum bid price for at least 10 consecutive business days before October 5, 2026.
• Continue development and commercialization efforts for seralutinib.

Key Dates

Recommendation

The reverse stock split is a necessary step to maintain Nasdaq listing, but it does not fundamentally change the company's underlying business prospects or the clinical development of its lead asset. While it avoids immediate delisting, it signals past struggles with stock price performance. Investors should monitor the company's ability to achieve sustained compliance and progress in its pipeline.

Keywords

reverse stock split, authorized shares, Nasdaq compliance, biopharmaceutical, pulmonary arterial hypertension, stock adjustment, listing requirements